Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of chronic kidney disease with dehydration incused by nausea and vomiting: a case report

Article Sidebar

PDF HTML
Submitted: October 23 2025
Published: Nov 3, 2025
DOI: 10.29328/journal.acr.1001170
Keywords:
Euglycemic Diabetic Ketoacidosis (EDKA), Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Empagliflozin, Metabolic acidosis, Dehydration and ketogenesis, Insulin infusion therapy, Glucagon and lipolysis mechanism, Adverse drug reaction in diabetes management
Crossref
Scopus
Google Scholar
Europe PMC

Main Article Content

Emad Hamdi Mahmoud
Department of Internal Medicine, Care Medical Al-Rawabi Hospital, Riyadh, Saudi Arabia
Olaa Awad Ismail
Department of Internal Medicine, Care Medical Al-Rawabi Hospital, Riyadh, Saudi Arabia

Article Details

Mahmoud, E. H., & Ismail, O. A. (2025). Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of chronic kidney disease with dehydration incused by nausea and vomiting: a case report. Archives of Case Reports, 339–341. https://doi.org/10.29328/journal.acr.1001170
Case Presentations

Copyright (c) 2025 Mahmoud EH, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

1. Zelniker TA, Wiviott SD. Cardiovascular and renal benefits vs risks of SGLT2 inhibitors. Lancet Diabetes Endocrinol. 2021.

2. Goldenberg RM. Clinical considerations for SGLT2 inhibitors. Can J Diabetes. 2022.

3. Peters AL. Diabetic ketoacidosis associated with SGLT2 inhibitors: review of cases. Diabetes Care. 2020.

4. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on acid–base balance. N Engl J Med. 2023.

5. Hine J, Paterson H. SGLT2 inhibitors and DKA: lessons from real-world experience. BMJ Open Diabetes Res Care. 2019.

6. Hamblin PS. Euglycemic diabetic ketoacidosis: clinical features and management. Diabetologia. 2019.

7. Dhatariya KK. Management of euglycemic diabetic ketoacidosis. Pract Diabetes. 2021.

8. Alkatheeri A, Alseddeeqi E. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitor: A case report. J Med Case Rep. 2022; 16(1):138. Available from: https://doi.org/10.1186/s13256-022-03347-1

9. Thawabi M. EDKA in patients on SGLT2 inhibitors: literature review and case analysis. Cureus. 2020.

10. Burke KR. Empagliflozin and ketoacidosis risk in patients with CKD. J Clin Endocrinol Metab. 2020.